Literature DB >> 10340686

Does loxapine have "atypical" properties? Clinical evidence.

W M Glazer1.   

Abstract

Given findings at a pharmacologic level that loxapine has a ratio of serotonin (5-HT2) and dopamine (D2) binding affinity similar to that of the atypical antipsychotics, 1 review data at a clinical level to see if this agent has correlating effects on symptoms and behaviors. I conclude that there is reason to infer that loxapine may be more beneficial for negative symptoms and refractory states than other typical antipsychotic agents. However, because of the limitations within these older studies, controlled fixed-dose designs employing current outcome methodologies are needed before concluding that loxapine is an atypical antipsychotic agent.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10340686

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  15 in total

Review 1.  Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).

Authors:  Edoardo G Ostinelli; Melanie J Brooke-Powney; Xue Li; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2017-07-31

2.  Loxapine add-on for adolescents and adults with autism spectrum disorders and irritability.

Authors:  Jessica A Hellings; Gregory Reed; Sharon E Cain; Xinghua Zhou; Francis X Barth; Michael G Aman; Gladys I Palaguachi; Dmytro Mikhnev; Rujia Teng; Rebecca Andridge; Marilyn Logan; Merlin G Butler; Joan C Han
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-03       Impact factor: 2.576

Review 3.  Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia.

Authors:  Gillian M Keating
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

4.  A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens.

Authors:  Zhu Li; Junji Ichikawa; Herbert Y Meltzer
Journal:  Psychopharmacology (Berl)       Date:  2003-03-28       Impact factor: 4.530

5.  Effect of loxapine on peripheral dopamine-like and serotonin receptors in patients with schizophrenia.

Authors:  Amarendra N Singh; Cia Barlas; Huma Saeedi; Ram K Mishra
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

Review 6.  Adverse Drug Reactions of Olanzapine, Clozapine and Loxapine in Children and Youth: A Systematic Pharmacogenetic Review.

Authors:  Diane Merino; Arnaud Fernandez; Alexandre O Gérard; Nouha Ben Othman; Fanny Rocher; Florence Askenazy; Céline Verstuyft; Milou-Daniel Drici; Susanne Thümmler
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

7.  Safety and tolerability of inhaled loxapine in subjects with asthma and chronic obstructive pulmonary disease--two randomized controlled trials.

Authors:  Nicholas Gross; Leon S Greos; Eli O Meltzer; Selwyn Spangenthal; Robert S Fishman; Daniel A Spyker; James V Cassella
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-12       Impact factor: 2.849

Review 8.  Discriminative stimulus properties of atypical and typical antipsychotic drugs: a review of preclinical studies.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2008-09-16       Impact factor: 4.530

9.  Delirious mania: can we get away with this concept? A case report and review of the literature.

Authors:  Rajshekhar Bipeta; Majeed A Khan
Journal:  Case Rep Psychiatry       Date:  2012-11-12

10.  Revisiting loxapine: a systematic review.

Authors:  Dina Popovic; Philippe Nuss; Eduard Vieta
Journal:  Ann Gen Psychiatry       Date:  2015-04-01       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.